Abstract:Background Amyloid plaque is one of the pathological hallmarks of Alzheimer's disease (AD). Anti⁃beta⁃amyloid (Aβ) immunotherapy is effective in removing brain Aβ, but has shown to be associated with detrimental effects. To avoid severe adverse effects such as meningoencephalitis induced by amyloid beta vaccine with adjuvant, and take advantage of amyloid beta antibody's therapeutic effect on Alzheimer's disease sufficiently, our group has developed a new Alzheimer vaccine with mutated amyloid beta 1-42 peptide stimulating dendritic cells (DC). Our previous work has confirmed that DC vaccine can induce adequate anti⁃amyloid beta antibody in PDAPP Tg mice safely and efficiently. The DC vaccine can improve impaired learning and memory in the Alzheimer's animal model, and did not cause microvasculitis, microhemorrhage or meningoencephalitis in the animal model. However, the exact mechanism of immunotherapy which reduces Aβ deposition remains unknown. In this report, we studied the mechanism of the vaccine, thinking that this may have implications for better understanding of the pathogenesis of Alzheimer's disease. Methods A new Alzheimer vaccine with mutated amyloid beta 1-42 peptide stimulating DC which were obtained from C57/B6 mouse bone marrow was developed. Amyloid beta with Freund's adjuvant was inoculated at the same time to act as positive control. After the treatment was done, the samples of brains were collected, fixed, cut. Immunohistochemical staining was performed to observe the expression of the nuclear hormone liver X receptor (LXR), membrane ⁃ bound protein tyrosine phosphatase (CD45), the ATP⁃binding cassette family of active transporters (ABCA1), receptor for advanced glycation end products (RAGE), β⁃site APP⁃cleaving enzyme (BACE) and Aβ in mouse brain tissue. Semi⁃ quantitative analysis was used to defect CA1, CA2, CA3, DG, Rad in hippocampus region and positive neuron in cortex region. Results Aβ was significantly reduced in the experimental group and the positive control group (P = 0.000), but no changes were seen in the negative control group. The levels of LXR, ABCA1, CD45, BACE expression were significantly higher in the PFDM group with DC vaccine treatment and the levels of RAGE were lower than those in the control group. Conclusion The reduction of Aβ via the DC vaccine occurs through multiple factors to achieve a new immune balance. The beneficial results of DC vaccine, which did not produce side effects, may be caused by the LXR/ABCA1 path. DC alone may play an important role in clearing the Aβ to prevent the occurrence of adverse reaction. DOI：10.3969/j.issn.1672⁃6731.2012.03.016

Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid- accumulation and improves cognition in APP/PS1 mice

Intracortical injection of immune checkpoint inhibitor promotes monocyte/macrophage infiltration and restores microglial function and neuronal activity in an AD mouse model

Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe/PS1dE9 mice.

The Combined Treatment of Amyloid-Β1-42-stimulated Bone Marrow–derived Dendritic Cells Plus Splenocytes from Young Mice Prevents the Development of Alzheimer's Disease in APPswe/PSENldE9 Mice

The Role of Mutated Amyloid Beta 1⁃42 Stimulating Dendritic Cells in a PDAPP Transgenic Mouse

A Coimmunization Vaccine of Aβ42 Ameliorates Cognitive Deficits Without Brain Inflammation in an Alzheimer’s Disease Model

Co-immunization with DNA and Protein Mixture: A Safe and Efficacious Immunotherapeutic Strategy for Alzheimer's Disease in PDAPP Mice

Programmed Cell Death Protein 1 Blockade Reduces Glycogen Synthase Kinase 3β Activity and Tau Hyperphosphorylation in Alzheimer’s Disease Mouse Models

Active Immunization with DNA Vaccine Reduced Cerebral Inflammation and Improved Cognitive Ability in APP/PS1 Transgenic Mice by In Vivo Electroporation

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid- had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

B lymphocytes ameliorate Alzheimer's disease-like neuropathology via interleukin-35

Vaccines targeting the primary amino acid sequence and conformational epitope of Aβ had distinct effects on neuropathology and cognitive deficits in EAE/AD mice.

A Multi-Targeting Immunotherapy Ameliorates Multiple Facets of Alzheimer’ S Disease in 3xtg Mice

Efficacy of a Therapeutic Vaccine Using Mutated Β-Amyloid Sensitized Dendritic Cells in Alzheimer’s Mice

B Lymphocytes Ameliorate Alzheimer’s Disease-Like Neuropathology Via Interleukin-35

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid‐β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer's disease in 3xTg mice

Active Aβ Vaccination-Induced Aβ Clearance Enhanced by Suppression of the CD40-CD40L Interaction (48.11)

Amelioration of Experimental Autoimmune Encephalomyelitis in Alzheimer’s Disease Mouse Models: A Potential Role for Aβ

Treatment with glatiramer acetate in APPswe/PS1dE9 mice at an early stage of Alzheimer's disease prior to amyloid-beta deposition delays the disease's pathological development and ameliorates cognitive decline

AVP(4-8) Improves Cognitive Behaviors and Hippocampal Synaptic Plasticity in the APP/PS1 Mouse Model of Alzheimer’s Disease